Neuroone Medical Technologies (NMTC) Investor update summary

Strategic partnerships and technology platform

• Four FDA-cleared devices, with three for brain applications and one for facial pain, supported by partnerships with Mayo Clinic and Zimmer Biomet.

• Zimmer Biomet holds exclusive distribution rights for brain-related devices and has contributed $8.5 million in licensing fees.

• Ongoing discussions for additional partnerships and licensing agreements across all device categories.

• Thin-film electrode platform enables both diagnostic and therapeutic functions, reducing surgeries and hospitalizations.

• Unique technology allows for less invasive procedures and customization of stimulation.

Product portfolio and market opportunity

• Product suite includes diagnostic electrodes, OneRF Ablation System (main revenue driver), Trigeminal Nerve Ablation System, spinal cord paddle lead, BVNA technology, and a drug delivery platform.

• All devices target multi-billion-dollar markets, including epilepsy, Parkinson’s, back pain, and drug delivery.

• OneRF Ablation System is the only FDA-cleared device for both diagnostic and therapeutic use in brain applications.

• Trigeminal Nerve Ablation System has shown all patients pain-free in limited market release; broader launch expected soon.

• Spinal cord and BVNA technologies aim to address large pain management markets with innovative delivery and ablation features.

Financial performance and guidance

• Fiscal Q1 product revenue reached $2.9 million, a 5.5% sequential increase, with a gross margin of 54.2%.

• Accounts receivable of $2.7 million from Zimmer Biomet has been fully collected.

• Baseline product revenue guidance for fiscal 2026 is at least $10.5 million, excluding potential upside from new products and international sales.

• Debt-free balance sheet with $3.6 million in cash at quarter end.